Adc Therapeutics SA is a biotechnology business based in the US. Adc Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. Adc Therapeutics employs 312 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $8.54 |
|---|---|
| 52-week range | $5.52 - $32.00 |
| 50-day moving average | $8.25 |
| 200-day moving average | $17.17 |
| Wall St. target price | $29.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.54 from 2022-07-01
| 1 week (2022-06-27) | 6.48% |
|---|---|
| 1 month (2022-06-03) | 18.61% |
| 3 months (2022-04-05) | -42.02% |
| 6 months (2022-01-05) | -56.41% |
| 1 year (2021-07-02) | -64.68% |
|---|---|
| 2 years (2020-07-02) | -83.27% |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Revenue TTM | $80.4 million |
|---|---|
| Gross profit TTM | $-125,478,000 |
| Return on assets TTM | -27.72% |
| Return on equity TTM | -84.74% |
| Profit margin | -242.69% |
| Book value | $2.12 |
| Market capitalisation | $656 million |
TTM: trailing 12 months
We're not expecting Adc Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Adc Therapeutics's shares have ranged in value from as little as $5.52 up to $32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Adc Therapeutics's is 1.9545. This would suggest that Adc Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B. V. , Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.